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ABSTRACT

Objectives: This study aims to determine the prevalence of vitamin D deficiency in Pakistani systemic lupus erythematosus (SLE) patients and the
effect of vitamin D deficiency on the severity and outcomes of SLE.
Patients and methods: This retrospective study evaluated SLE patients presenting to our hospital between January 2009 and December 2018.
A total of 98 patients (13 males, 85 females; mean age 39.8±14.9 years; range, 16 to 73 years) with vitamin D levels available at the time of diagnosis
were included in the study. Disease activity was measured using SLE disease activity score at the time of diagnosis and at the two-year mark.
Results: Sixty-five patients were deficient in Vitamin D and out of those 46 were severely deficient. The severe disease group had more patients with
vitamin D deficiency at both visits (43/78 and 33/46) while patients in remission all had normal vitamin D (12/12 and 14/14) (p≤0.001).
Conclusion: Vitamin D deficiency is common in SLE patients and also significantly associated with increased disease activity at the time of diagnosis
and at the two-year mark. We hope this study becomes a platform for the global medical community to come together and implement early
screening and monitoring of vitamin D levels and to determine the optimal level of supplementation for prevention of poor outcomes in SLE.
Keywords: Autoimmune disease, rheumatology, systemic lupus erythematosus, vitamin D.

Vitamin D is the common denomination
of a collection of sterols belonging to a
class of secosteroids playing a vital role in
phosphocalcic metabolism. The main circulating
form of vitamin D is 25-hydroxy vitamin D
(25-(OH)D) formed by hydroxylation of
cholecalciferol in the liver.1,2 Its function is
mediated through the vitamin D receptors (VDRs)
which are not only found in bones and kidney
but also in muscles.1 Immune cells including
the dendritic cells, macrophages, monocytes,
and lymphocytes (B and T cells) are capable
of converting 25-(OH)D3 to 1,25-(OH)2D3,
theoretically endowing the immunocytes with a

higher level of vitamin D-related immune response
control at the inflamed sites and demonstrating
the important role that vitamin D has in the
immune system.2 Another piece of evidence
that suggests a potential role of vitamin D in the
immune system and the mediation of autoimmune
diseases is the presence of VDR polymorphisms,
namely, ApaI, FokI, BsmI, and TaqI, which have
been found to be associated with the development
of autoimmunity.2,3
Systemic lupus erythematosus (SLE) is a
multisystem autoimmune inflammatory disease
mainly affecting females of childbearing age. It
is characterized by a large spectrum of clinical
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manifestations accompanied by prototypic
abnormalities of the immune system characterized
by immune-complex induced inflammation.4
One of the most effective ways of assessing
severity of this disease is by continuously
monitoring disease activity which also helps
in determining prognosis and extent of organ
damage, ultimately dictating the treatment
modality. The SLE Disease Activity Index 2000
(SLEDAI-2K) has been the most widely used
SLE disease activity measure.5 However, the
performance of SLEDAI in detecting clinically
meaningful changes in disease activity is
limited, since each item of SLEDAI is scored
dichotomically, with the same numerical weight
regardless of the severity of change observed.6 In
addition, potentially severe lupus manifestations,
such as hemolytic anemia, pneumonitis, types
of rash, and systemic vasculitis are not scored in
SLEDAI.6
These limitations had important implications
on target-driven management of SLE in daily
clinical practice, and in assessing the efficacy of
new medications in clinical trials. Thus, there was
an urgent need for a new tool which was able to
accurately capture clinically meaningful changes
in SLE disease activity. Jesus et al.,6 validated
a new tool for the measurement of SLE disease
activity: the SLE disease activity score (SLE-DAS).
This provides an accurate, continuous, and userfriendly global measure of SLE disease activity
with improved sensitivity to change and high
specificity, in comparison to SLEDAI-2K.
Systemic lupus erythematosus patients are at
a heightened risk of being deficient in vitamin D
due to reduced exposure to the sun, renal damage,
and continuous use of medications (such as
chronic steroids and hydroxychloroquine) with
the potential of altering metabolism of vitamin D.7
SLE has been found to be substantially T-cell
driven with the T helper type 1 (Th1) and Th17
cluster of differentiation 4+ T cells being chiefly
responsible for driving the pro-inflammatory
response in SLE.8 As 1,25-(OH)2D3 dampens
the pro-inflammatory response of Th17, it is
theoretically possible to suppress the SLE disease
with vitamin D treatment.
Studies from around the world have stated
the prevalence of vitamin D deficiency in SLE
patients to be varied but up to 90% in some
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articles.1,9 Unfortunately, there is scarcity of local
data to look for vitamin D status in autoimmune
diseases. Only two articles were found that show
the relationship of vitamin D with rheumatoid
arthritis and vitiligo in Pakistani population;10,11
however, to our knowledge, no study has been
conducted investigating the association of SLE and
vitamin D in Pakistani population. Therefore, in
this study, we aimed to determine the prevalence
of vitamin D deficiency in Pakistani SLE patients
and the effect of vitamin D deficiency on the
severity and outcomes of SLE.

PATIENTS AND METHODS
This retrospective study was conducted at
Department of Medicine, Aga Khan University
Hospital. A total of 500 patients were diagnosed
as SLE during hospital stay or clinic appointment
between January 2009 and December 2018.
Diagnosis of SLE was confirmed by applying
the Systemic Lupus International Collaborating
Clinics-12 criteria.12 This visit was characterized
as the first visit (even if the patient had disease
previously or had been newly diagnosed) to
the hospital and vitamin D levels were noted
from this visit. The second visit of the patient
was taken after 48 months and disease activity
was assessed at both visits and then compared
with relation to vitamin D level. Patients with
vitamin D not checked within one week of the
first visit or those who were already on vitamin D
supplements, or had other existing connective
tissue diseases, hepatitis B, hepatitis C,
human immunodeficiency virus, sarcoidosis,
parathyroid disorders, chronic liver disease, or
chronic kidney disease were excluded. Finally,
98 patients (13 males, 85 females; mean age:
39.8±14.9 years; range, 16 to 73 years) were
included. The study protocol was approved by
the Ethical Review Committee of the Aga Khan
University Hospital. A written informed consent
was obtained from each patient. The study was
conducted in accordance with the principles of
the Declaration of Helsinki.
The data were collected from the medical
records of patients using a pre-designed pro forma.
Information collected included demographics,
clinical characteristics of SLE, vitamin D levels,
and SLE-DAS at the time of diagnosis and at
the two-year mark. Disease activity was also
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analysis. Qualitative variables were presented
as frequency and percentages and continuous
variables as mean with standard deviation. For
continuous variables, we used Student t-test
or Wilcoxon rank-sum test and chi-square test
or Fisher exact test for categorical variables
to identify differences between the vitamin D
deficient and non-deficient groups. P value
less than 0.05 was considered statistically
significant.

monitored via complement component (C) 3,
C4, and anti-double-stranded deoxyribonucleic
acid (anti-dsDNA). Anti-dsDNA was labeled as
positive with values of greater than 25 IU/mL
while C3 and C4 values of less than 0.8 and
0.1 were considered as significant. Vitamin D
levels were categorized as normal (more than
20 ng/mL), mild deficiency (less than 20 ng/mL),
and severe deficiency (less than 12 ng/mL).
SLE-DAS was used to calculate DAS at both visits
and then on the basis of the score, the disease
was appropriately categorized as remission (less
than 2.08), low disease activity (less than 3.77),
moderate disease activity (less than 7.64), and
severe disease activity (more than 7.64).6

RESULTS
Among the included patients, 87%
were females and the mean age at the
time of diagnosis was 39.8±14.9 years
(range, 16 to 73 years). The most common
clinical manifestations were mucosal ulcers

Statistical analysis
The IBM SPSS version 22.0 software (IBM
Corp., Armonk, NY, USA) was used for statistical

Table 1. Comparison of demographics and clinical characteristics of systemic lupus erythematosus patients according
to level of vitamin D deficiency
Level of vitamin D deficiency
Overall
(n=98)

Normal vitamin D
level (n=33)

Mild vitamin D
deficiency (n=29)

Severe vitamin D
deficiency (n=46)

n

n

n

n

Age (year)
<45
>45

64
34

23
10

12
7

29
17

Sex
Male
Female

13
85

6
27

2
17

5
41

Residence
Urban
Rural

67
31

22
11

13
6

32
14

p
0.809

0.593

0.963

Arthritis

51

15

12

24

0.469

Localized rash

44

14

11

19

0.445

Generalized rash

24

8

3

13

0.568

Alopecia

21

7

1

13

0.121

Mucosal ulcers

56

16

10

30

0.302

Systemic vasculitis

25

6

6

13

0.476

Mucocutaneous vasculitis

21

8

2

11

0.435

Neuropsychiatric symptoms

12

1

1

10

0.026

Serositis

20

4

1

15

0.016

Cardiopulmonary features

23

3

3

17

0.011

Myositis

19

2

2

15

0.007

Proteinuria

29

9

2

18

0.067

Leukopenia

15

3

5

7

0.252

Hemolytic anemia

31

4

5

22

0.001

Thrombocytopenia

31

3

6

22

0.003
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with neuropsychiatric symptoms, serositis,
cardiopulmonary features, myositis, hemolytic
anemia, and thrombocytopenia (p≤0.05).

R 2 Linear=0.208
60

DAS (second visit)

50

The overall mean SLE-DASs at diagnosis
and at the two-year mark were 30.9±19.0
(range, 0 to 80) and 10.9±10.4 (range, 0 to 54),
respectively. Figure 1 illustrates the inverse
relationship between the vitamin D levels and
the SLE-DASs. Table 2 shows the comparison
between vitamin D levels and SLE disease
activity indicators. C3 and C4 levels showed
a significant association with vitamin D levels
(p≤0.05). Furthermore, there was a significant
association between SLE-DAS status and vitamin
D deficiency. The severe disease group had more
patients with vitamin D deficiency at both visits
(43/78 and 33/46) while patients in remission
all had normal vitamin D (12/12 and 14/14)
(p≤0.001).

40

30

20
Y=16.15+0.27*x
10

0
0.00

20.00

40.00

60.00

80.00

100.00

Vitamin D level at first visit

Figure 1. Scatter plot showing inverse relationship
between vitamin D levels and systemic lupus erythematosus
disease activity scores at end of study period (48 months
after first visit).
DAS: Disease activity score.

DISCUSSION

(n=56; 57%), arthritis (n=51; 52%), and
localized rash (n=44; 452%). Mean vitamin
D level was 19.9±17.8 (range, 1.5 to 85.9).
Sixty-five patients were deficient in Vitamin D
and out of those 46 were severely deficient.
Table 1 compares the clinical characteristics
of SLE with vitamin D level status. Severe
vitamin D deficiency was significantly associated

The role of vitamin D and the impact of its
deficiency on multiple autoimmune diseases have
long been a subject of discussion in the medical
literature. SLE patients have a complicated
relationship with vitamin D. The reason behind
this is because some researchers believe that

Table 2. Comparison of systemic lupus erythematosus disease activity indicators according to level of vitamin D
deficiency
Level of vitamin D deficiency
Overall
(n=98)

Normal vitamin D
level (n=33)

Mild vitamin D
deficiency (n=29)

Severe vitamin D
deficiency (n=46)

n

n

n

n

p
0.184

ANA

62

17

12

33

Anti-dsDNA

68

19

14

35

0.192

Decreased C3 and C4

41

8

11

22

0.032

SLE-DAS (first visit)
Severe
Moderate
Mild
Remission

78
6
2
12

17
2
2
12

18
1
0
0

18
1
0
0

SLE-DAS (second visit)
Severe
Moderate
Mild
Remission

46
26
12
14

3
10
6
14

10
6
3
0

33
10
3
0

0.001

0.001

ANA: Antinuclear antibody; Anti-dsDNA: Anti-double-stranded deoxyribonucleic acid antibody; C3 and C4: Complement components 3 and 4; SLE-DAS: Systemic lupus
erythematosus-disease activity score.
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SLE patients have multiple risk factors resulting
in vitamin D deficiency, while the rest are of the
opinion that vitamin D deficiency is itself a cause
of SLE in such patients.9
The results of this study have demonstrated
that vitamin D deficiency is an extremely common
occurrence in SLE patients with two thirds being
deficient and more than half being severely
deficient. It has also showed that there is a strong
association between vitamin D deficiency and
disease activity. Other studies have displayed a
similar level of prevalence which ranges from
16 to 96% and can vary depending on a number
of factors such as environmental, geographical,
and genetic factors.13
The mean vitamin D level in the present study
was 19.8±17.8 ng/mL, which is almost similar to
that seen in Egypt (17.6±6.9 ng/mL), Saudi Arabia
(19.1±9.5 ng/mL), and Spain (22 ng/mL).1,9,14 In
contrast, an Indian study reported very low mean
vitamin D level of around 11.61.15 However,
prevalence of vitamin D deficiency in the present
study was around 64.3% which is quite lower
than all four studies above which have mentioned
a prevalence of greater than 90% in each. As
this is a retrospective study, this might be due to
the poor data record.
There are few studies evaluating the association
of vitamin D deficiency and SLE disease activity
and even fewer assessing long-term outcomes.
Our study demonstrates an inverse relationship
between vitamin D levels and SLE disease
activity. Patients with vitamin D deficiency had
a significantly higher disease activity at the
time of diagnosis and two years later. A recent
report by Amital et al.16 displayed similar results
using the SLEDAI and European Consensus
Lupus Activity Measurement scoring systems, and
presented an inverse correlation between the two
variables. Similarly, Ben-Zvi et al.17 also reported
an increasing trend of disease activity with
decreasing vitamin D levels. Dutta et al.,18 in their
very recent study from India, concluded that the
vitamin D deficient group was three times more
likely of developing high disease activity (odds
ratio: 3.9; p<0.05) compared with the control
group.
This study has some limitations. The findings
of the study are limited due to a retrospective
study design, small sample size because of fewer

patients having recorded Vitamin D levels and due
to the use of a new scale for assessing disease
severity which has not been used at a big scale.
Furthermore, since the majority of the patients
presenting to our tertiary hospital had either
been previously admitted elsewhere or were from
far-flung areas, true vitamin D values could not be
found. Another problem with retrospective data
collection was the quality of the data in the file
and the variability in the examinations performed
by physicians. Still, this study is the first of its
kind from Pakistan which assesses the prevalence
of vitamin D deficiency in SLE patients and also
demonstrates the association between vitamin D
deficiency and SLE disease activity. It offers new
local information to clinicians which can influence
clinical practice. However, to better understand
the impact of vitamin D deficiency on SLE
patients and to assess its prognostic significance,
further specifically designed prospective cohort
studies are needed.
In conclusion, vitamin D deficiency is
prevalent in SLE patients and is significantly
associated with more active disease at the time
of diagnosis and at the two-year mark. We
hope this study becomes a platform for the
global medical community to come together and
implement early screening and monitoring of
vitamin D levels and to determine the optimal
level of supplementation for prevention of poor
outcomes in SLE.
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